| Offering Information |
| Expected Date | WITHDRAWN |
| Proposed Exchange/Ticker |
Nasdaq: XANO |
| Security Type |
Common Stock |
| Lead Underwriter |
Morgan Stanley |
| Days In Registration |
350 |
| Date Filed |
9-Nov-2007 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Xanodyne Pharmaceuticals Inc, located in Newport, Kentucky, manufactures prescription pharmaceuticals intended for final consumption, including biotech products and antibiotics. The company was incorporated under the laws of the State of Delaware in May 2000 under the name UBE Pharmaceuticals, Inc, then it changed its name to Xanodyne Pharmacal, Inc in June 2001 and to Xanodyne Pharmaceuticals, Inc in February 2004. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
- |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
- |
| · As a Percent |
- |
| Overallotment Shares Filed |
- |
| File Amount |
- |
| File Price Range |
- - - |
| File Mid Price |
- |
|
